BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 36356462)

  • 21. Extent of disease in recurrent prostate cancer determined by [(68)Ga]PSMA-HBED-CC PET/CT in relation to PSA levels, PSA doubling time and Gleason score.
    Verburg FA; Pfister D; Heidenreich A; Vogg A; Drude NI; Vöö S; Mottaghy FM; Behrendt FF
    Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):397-403. PubMed ID: 26563121
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Retrospective study of predictors of bone metastasis in prostate cancer cases.
    Ho CC; Seong PK; Zainuddin ZM; Abdul Manaf MR; Parameswaran M; Razack AH
    Asian Pac J Cancer Prev; 2013; 14(5):3289-92. PubMed ID: 23803117
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical parameters and nomograms for predicting lymph node metastasis detected with
    Onal C; Ozyigit G; Oymak E; Guler OC; Hurmuz P; Tilki B; Reyhan M; Tuncel M; Akyol F
    Prostate; 2021 Jul; 81(10):648-656. PubMed ID: 33949694
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinico-pathologic characterisation of metastatic prostate cancer in the Radiotherapy and Oncology Department, Ahmadu Bello University Teaching Hospital, Zaria-Nigeria: 2006-2009.
    Adewuyi SA; Mbibu NH; Samaila MO; Ketiku KK; Durosinmi-Etti FA
    Niger Postgrad Med J; 2013 Mar; 20(1):45-51. PubMed ID: 23661210
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Retrospective analysis of risk factors for bone metastasis in newly diagnosed prostate cancer patients.
    Peng C; Juan C; Mao W; Jinghe Y; Renli T
    Eur Rev Med Pharmacol Sci; 2022 Jun; 26(11):3832-3839. PubMed ID: 35731052
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characterization of osteoblastic and osteolytic proteins in prostate cancer bone metastases.
    Larson SR; Zhang X; Dumpit R; Coleman I; Lakely B; Roudier M; Higano CS; True LD; Lange PH; Montgomery B; Corey E; Nelson PS; Vessella RL; Morrissey C
    Prostate; 2013 Jun; 73(9):932-40. PubMed ID: 23334979
    [TBL] [Abstract][Full Text] [Related]  

  • 27. When to perform bone scintigraphy in patients with newly diagnosed prostate cancer? a retrospective study.
    Lin Y; Mao Q; Chen B; Wang L; Liu B; Zheng X; Xie L
    BMC Urol; 2017 Jun; 17(1):41. PubMed ID: 28606069
    [TBL] [Abstract][Full Text] [Related]  

  • 28. When to perform bone scan in patients with newly diagnosed prostate cancer: external validation of a novel risk stratification tool.
    De Nunzio C; Leonardo C; Franco G; Esperto F; Brassetti A; Simonelli G; Dente D; De Dominicis C; Tubaro A
    World J Urol; 2013 Apr; 31(2):365-9. PubMed ID: 22576696
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 68Ga-PSMA-11 PET/CT in Newly Diagnosed Prostate Adenocarcinoma.
    Ergül N; Yilmaz Güneş B; Yücetaş U; Toktaş MG; Çermik TF
    Clin Nucl Med; 2018 Dec; 43(12):e422-e427. PubMed ID: 30273204
    [TBL] [Abstract][Full Text] [Related]  

  • 30. When to perform bone scan in patients with newly diagnosed prostate cancer: external validation of the currently available guidelines and proposal of a novel risk stratification tool.
    Briganti A; Passoni N; Ferrari M; Capitanio U; Suardi N; Gallina A; Da Pozzo LF; Picchio M; Di Girolamo V; Salonia A; Gianolli L; Messa C; Rigatti P; Montorsi F
    Eur Urol; 2010 Apr; 57(4):551-8. PubMed ID: 20034730
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prostate cancer in patients from rural and suburban areas--PSA value, Gleason score and presence of metastases in bone scan.
    Szot W; Kostkiewicz M; Zając J; Owoc A; Bojar I
    Ann Agric Environ Med; 2014; 21(4):888-92. PubMed ID: 25528940
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diagnostic Role of Serum Free-to-Total Prostate Specific Antigen (PSA) Ratio in Prostate Cancer with Serum Total Concentration of PSA below 4 ng/mL.
    Chang CC; Lee YC; Tsai HW; Yii SC; Yen TH; Chu FY
    Asian Pac J Cancer Prev; 2015; 16(13):5261-4. PubMed ID: 26225663
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 11C-Choline PET/CT in the primary diagnosis of prostate cancer: impact on treatment planning.
    Garcia JR; Jorcano S; Soler M; Linero D; Moragas M; Riera E; Miralbell R; Lomeña F
    Q J Nucl Med Mol Imaging; 2015 Sep; 59(3):342-50. PubMed ID: 24844254
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Men presenting with prostate-specific antigen (PSA) values of over 100 ng/mL.
    Ang M; Rajcic B; Foreman D; Moretti K; O'Callaghan ME
    BJU Int; 2016 Apr; 117 Suppl 4():68-75. PubMed ID: 26890320
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Single-center study of the abnormal concentration of bone imaging agent and prostate cancer bone metastasis prediction model].
    Cheng Y; Luo LP; Hu S; Li LN; Wu C; Wu B; Wang DW
    Zhonghua Zhong Liu Za Zhi; 2020 Oct; 42(10):876-881. PubMed ID: 33113631
    [No Abstract]   [Full Text] [Related]  

  • 36. Prediction of metastatic prostate cancer by prostate-specific antigen in combination with T stage and Gleason Grade: Nationwide, population-based register study.
    Thomsen FB; Westerberg M; Garmo H; Robinson D; Holmberg L; Ulmert HD; Stattin P
    PLoS One; 2020; 15(1):e0228447. PubMed ID: 31995611
    [TBL] [Abstract][Full Text] [Related]  

  • 37.
    Vinsensia M; Chyoke PL; Hadaschik B; Holland-Letz T; Moltz J; Kopka K; Rauscher I; Mier W; Schwaiger M; Haberkorn U; Mauer T; Kratochwil C; Eiber M; Giesel FL
    J Nucl Med; 2017 Dec; 58(12):1949-1955. PubMed ID: 28637799
    [No Abstract]   [Full Text] [Related]  

  • 38. Predictors of bone metastasis in pre-treatment staging of asymptomatic treatment-naïve patients with prostate cancer.
    Moslehi M; Cheki M; Salehi-Marzijarani M; Amuchastegui T; Gholamrezanezhad A
    Rev Esp Med Nucl Imagen Mol; 2013; 32(5):286-9. PubMed ID: 23478119
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Outcomes of men with an elevated prostate-specific antigen (PSA) level as their sole preoperative intermediate- or high-risk feature.
    Faisal FA; Sundi D; Pierorazio PM; Ball MW; Humphreys EB; Han M; Epstein JI; Partin AW; Carter HB; Bivalacqua TJ; Schaeffer EM; Ross AE
    BJU Int; 2014 Dec; 114(6b):E120-E129. PubMed ID: 24731026
    [TBL] [Abstract][Full Text] [Related]  

  • 40. External validation of the Briganti nomogram to estimate the probability of specimen-confined disease in patients with high-risk prostate cancer.
    Roumiguié M; Beauval JB; Filleron T; Benoit T; Rischmann P; de la Taille A; Salomon L; Soulié M; Malavaud B; Ploussard G
    BJU Int; 2014 Dec; 114(6b):E113-E119. PubMed ID: 24684584
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.